Evidence map›Paper›PMID 32949147›Full record

ArticleBiometrics2021

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials.

Nima S Hejazi, Mark J van der Laan, Holly E Janes, Peter B Gilbert, David C Benkeser

Abstract read
In one paragraph

Article in Biometrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nima S HejaziGraduate Group in Biostatistics, University of California, Berkeley, California.ORCID 0000-0002-7127-2789
Mark J van der LaanDivision of Epidemiology & Biostatistics, School of Public Health, University of California, Berkeley, California.ORCID 0000-0003-1432-5511
Holly E JanesVaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-3237-984X
Peter B GilbertVaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-2662-9427
David C BenkeserDepartment of Biostatistics & Computational Biology, Rollins School of Public Health, Emory University, Atlanta, Georgia.ORCID 0000-0002-1019-8343

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Statistical Methods in HIV Vaccine Efficacy TrialsR37AI054165 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert · 2010 to 2026
$6.7M
Targeted Learning using adaptive designs for HIV Epidemic control in East AfricaR01AI074345 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PETERSEN, MAYA LIV, VANDERLAAN, MARK J · 2007 to 2023
$6.6M
Biomedical Big Data Training Program at UC BerkeleyT32LM012417 · NLM · UNIVERSITY OF CALIFORNIA BERKELEY · PI JORDAN, MICHAEL, NIELSEN, RASMUS · 2016 to 2020
$1.4M
NIAID NIH HHS R01 AI074345NIAID NIH HHS R37 AI054165NIAID NIH HHS UM1 AI068635NLM NIH HHS T32 LM012417
6 · The paper itself

Abstract

The advent and subsequent widespread availability of preventive vaccines has altered the course of public health over the past century. Despite this success, effective vaccines to prevent many high-burden diseases, including human immunodeficiency virus (HIV), have been slow to develop. Vaccine development can be aided by the identification of immune response markers that serve as effective surrogates for clinically significant infection or disease endpoints. However, measuring immune response marker activity is often costly, which has motivated the usage of two-phase sampling for immune response evaluation in clinical trials of preventive vaccines. In such trials, the measurement of immunological markers is performed on a subset of trial participants, where enrollment in this second phase is potentially contingent on the observed study outcome and other participant-level information. We propose nonparametric methodology for efficiently estimating a counterfactual parameter that quantifies the impact of a given immune response marker on the subsequent probability of infection. Along the way, we fill in theoretical gaps pertaining to the asymptotic behavior of nonparametric efficient estimators in the context of two-phase sampling, including a multiple robustness property enjoyed by our estimators. Techniques for constructing confidence intervals and hypothesis tests are presented, and an open source software implementation of the methodology, the txshift R package, is introduced. We illustrate the proposed techniques using data from a recent preventive HIV vaccine efficacy trial.

Indexed as

AIDS VaccinesHIV InfectionsClinical Trials as TopicHumansProbabilityVaccine EfficacyAIDS Vaccinescausal inferencestochastic interventionstargeted minimum loss estimationtwo-phase samplingvaccine efficacy

Identifiers

PMID32949147
PMCPMC8016405

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.